HighTide Therapeutics, Inc. (HKG:2511)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.930
-0.170 (-5.48%)
Jun 18, 2026, 3:12 PM HKT
Market Cap1.77B +29.8%
Revenue (ttm)n/a
Net Income-272.60M
EPS-0.57
Shares Out 571.33M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume708,500
Open3.100
Previous Close3.100
Day's Range2.840 - 3.100
52-Week Range1.800 - 4.720
Beta-0.30
AnalystsStrong Buy
Price Target8.07 (+175.43%)
Earnings DateAug 25, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase I clinical trial to treat gradual loss of kidney function over time; phase IIb for the treatment of pathogenetic complexity and heterogeneity; phase I to treat obesity; and phase II for the treatment of chronic cholestatic liver disea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 51
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2511
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements